This Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate mechanisms for enhancing the motor function of fecal continence muscles to improve fecal incontinence in patients. The $862,002 award to The Medical College of Wisconsin, Inc. will fund a 5-year study to characterize the fatigability of continence muscles and determine...
Dignify Therapeutics, LLC was awarded a $1.88 million Project Grant from the Defense Health Agency through the Military Medical Research and Development Program to support research titled "Intrarectal Mechanoreceptor Sensitization to Induce Defecation After Spinal Injury" from September 1, 2023 to August 31, 2025. The grant will support Dignify Therapeutics' ongoing efforts to develop novel therapeutics targeting sacral spinal cord neurons involved in continence and sexual function for...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $324,678 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Lumina Medical LLC, a for-profit limited liability company located in Culver City, California. The grant supports the development of a motorized, girth-adjustable anal dilator device designed to improve patient adherence to anal dilation treatments for conditions such as anismus and anal...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,712,226 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Orphagen Pharmaceuticals, Inc. The grant supports the development of a novel, first-in-class class of small molecule antagonists that inhibit the gut migration of activated T cells, which is a promising therapeutic approach for treating inflammatory bowel disease (IBD). Preliminary data...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will fund research to investigate the role of urothelial cells in bladder sensory function and pain signaling. The $521,019 award to The Medical College of Wisconsin, Inc. aims to functionally and molecularly identify the sensory neuron populations that respond to urothelial cell...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $708,138 to support the development of a biomechanocompatible small molecule-releasing scaffold for bladder augmentation. The goal is to create an alternative to conventional surgical approaches that use detubularized bowel tissue, which can have significant complications. The...
The National Institute on Aging (CFDA 93.866 Aging Research) awarded a $389,852 Project Grant to Dignify Therapeutics, LLC to develop novel drug formulations for treating urinary incontinence (UI) and overactive bladder (OAB) symptoms in the elderly. The grant supports a research project to create new intravesical (bladder-instilled) drug therapies that can block pain-sensing neurons and provide long-term relief of UI and OAB for elderly patients who are unresponsive to current treatments. The...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop and test optimized formulations of a combination drug therapy for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The $318,488 award will fund feasibility studies in dogs and mice to identify the most desirable pharmacokinetic parameters and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $878,256 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Novagyn LLC, a woman-owned small business in New Hampshire. The goal of this Phase I STTR project is to establish the feasibility of a naturally-derived, coaxial electrospun scaffold as an alternative to synthetic surgical mesh for treating stress urinary incontinence in women. The project...
This $675,480 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to develop a novel therapeutic compound for treating chronic kidney disease (CKD). The awardee, Fibrotherapeutics Inc., is conducting preclinical studies to evaluate the efficacy, safety, and therapeutic index of a modified, water-soluble, orally-active peptide derived...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on developing a therapy for fecal incontinence and fecal urgency. The $782,916 award to Dignify Therapeutics, LLC aims to inhibit colorectal afferent terminals as a means to safely and effectively prevent or reduce the symptoms of fecal incontinence and urgency, as well as associated pain and discomfort. The first specific aim is to examine the effects of proprietary compounds on colorectal function and establish the duration of colorectal afferent inhibition to guide dosing. Future plans include testing the optimized compound in a translational animal model, initiating IND-enabling studies, and examining the effects on rectal afferent fibers to provide mechanistic insights.